Silodosin: a guide to its use in benign prostatic hyperplasia


    loading  Checking for direct PDF access through Ovid

Abstract

The highly selective α1A-adrenergic receptor antagonist silodosin rapidly improves the signs and symptoms of benign prostatic hyperplasia (BPH). Oral silodosin is generally well tolerated in men with BPH, with a favourable cardiovascular tolerability profile. Abnormal ejaculation is the most commonly reported adverse effect associated with silodosin therapy; however, only 3.9% of patients discontinued treatment due to this event.

    loading  Loading Related Articles